Recent News
Much of the meeting came for the next CAR T readout. AB-101 drew attention for a different reason. It depletes B cells by a completely different route.Read Article
LLMs in SLE: From Patient Education to Clinical Decision Support
The emergence of large language models (LLMs) represents a promising shift in how complex diseases such as systemic lupus erythematosus (SLE) are communicated and interpreted across both patient and clinical settings. Two EULAR 2026 abstracts highlight the evolving role of LLMs across this spectrum, from patient-facing education to diagnostic reasoning.
Read Article
An IL-23i through ~5 years: How did clinical manifestations of PsA and radiographic progression change during long-term treatment?
🔥View the latest long-term data from ACR to find out more. Sponsored by AbbVie Medical Affairs + Health Impact.
https://t.co/mT6WkG6Q6D https://t.co/DRRqRmMkwL
Dr. John Cush @RheumNow ( View Tweet)
New: Classification Criteria and Recommendations in SpA
ASAS and SPARTAN have updated their key classification criteria for axSpA. EULAR has also recently revised its recommendations on the role of imaging in the diagnosis and clinical management of SpA. https://t.co/YOWfwTkbqp
Dr. John Cush @RheumNow ( View Tweet)
Synovio-entheseal inflammation and the tipping point from PsO to PsA
Psoriatic arthritis develops in approximately 20 to 30 per cent of patients with psoriasis, yet predicting which patients will make the transition and when, has remained one of the most clinically challenging questions in rheumatology. A study presented at EULAR 2026 provides the most granular ultrasound characterisation yet of the journey from psoriasis, through subclinical disease, to early clinical PsA. The study identifies the specific
Read Article
Lessons on Non-adherence
Dr. Sun et al. from Duke University presented abstract POS0692 during one of the poster sessions entitled, “Lupus patients with concurrent inflammatory activity and symptom burdens have the lowest medication adherence and experience distinct adherence barriers.” They evaluated differences in self-reported medication adherence and reasons for nonadherence across Type 1 & 2 SLE classification groups, with a prespecified focus on
Read Article
Improving Referrals for Inflammatory Arthritis
Dr. Antoni Chan discusses abstracts POS1284 and POS0784 presented at EULAR 2026 in London
https://t.co/p1iT8yPNzF https://t.co/gEyuEwW4aj
Dr. John Cush @RheumNow ( View Tweet)
Gout and ULT Withdrawal -- The GO TEST FINALE Trial
Professor Noortje van Herwaarden reviews abstract OP001 at EULAR 2026 in London
https://t.co/d8U1168SRn https://t.co/hP0EUrciTu
Dr. John Cush @RheumNow ( View Tweet)
Day 3 Recap: EULAR 2026
Join Drs. Jack Cush, Jiha Lee, Nelly Ziade, and Sheila Reyes for a lively discussion. Abstracts discussed included: OP0348 POS0290 OP0342 POS1068 POS0201 POS0288
https://t.co/TSnVVOpF75 https://t.co/EFD0WKRpF4
Dr. John Cush @RheumNow ( View Tweet)
Exploring Idiopathic Myopathies
#EULAR2026: Idiopathic inflammatory myopathies (IIM) are a diverse group of autoimmune diseases with significant morbidity. While EULAR/ACR classification criteria were established in 2017, updated real-world data and better tools to assess https://t.co/CbUWodWT7z
Dr. John Cush @RheumNow ( View Tweet)
What’s New in Psoriatic Arthritis: A Whirlwind Tour
At #EULAR2026, Prof. Dennis McGonagle highlighted three key PsA trends: the rise of single-cell and spatial transcriptomics, progress toward personalized care (though not yet fully realized), and the next frontier of defining https://t.co/IzsSzx6Pc9
Dr. John Cush @RheumNow ( View Tweet)
Seeing more or seeing too much? Ultrasound vs MRI in preclinical RA
Imaging in the preclinical phase of RA is moving fast—arguably faster than our ability to interpret what we are actually seeing. Across EULAR 2026 abstracts, a consistent theme emerges: we are improving detection of subclinical inflammation, but still struggling to determine what level of detection is clinically meaningful.
Read Article
What’s New in Macrophage Activation Syndrome Therapeutics
MAS, the most severe complication of Still’s disease, is increasingly recognized as a cytokine-driven hyperinflammatory state centered on interferon gamma (IFNγ). Therapeutic advances presented at EULAR 2026 demonstrate both consolidation of established pathways and expansion into novel biologic strategies.
Read Article
Strike First: TNFi vs. Step-Up Therapy in Early Peripheral SpA
The approach to treating peripheral SpA has remained the same for a long time. The guidelines recommend starting with NSAIDs, escalating to conventional synthetic DMARDs, typically sulfasalazine or methotrexate, and https://t.co/iEqzp6FStv
Dr. John Cush @RheumNow ( View Tweet)
Day 2 Report from EULAR 2026
Day two at EULAR 2026 was jammed with sessions on advances in immune checkpoint inhhbitors (and irAEs), Lupus, Scleroderma, RA and IgG4 related disease. Here are a few of my favorites from Day 2
https://t.co/6KwtkMNLAf https://t.co/Toh4HNZFN5
Dr. John Cush @RheumNow ( View Tweet)
Are we failing in the treatment of RA-ILD?
Dr. Janet Pope discusses treatment of RA-ILD after attending the "How to Treat (HOT)" session on RA-ILD at EULAR 2026.
https://t.co/3UpQQE22Nz https://t.co/ULdCOgh7pY
Dr. John Cush @RheumNow ( View Tweet)
RA-ILD: Screening risk and genetic susceptibility
Two abstracts presented at EULAR 2026 add important insights into identifying patients at risk for RA-ILD and understanding the genetic mechanisms that may underpin disease development.
https://t.co/VoY3HFjbjf https://t.co/vPzLvBAWKJ
Dr. John Cush @RheumNow ( View Tweet)
MRI as a novel biomarker in lupus
The clinical abstract sessions at #EULAR2026 on diagnostic tools in lupus showcased interesting studies, including the use of MRI, as potential non-invasive biomarkers.
https://t.co/TK2gqSxAg5 https://t.co/5Qj8KXWgub
Dr. John Cush @RheumNow ( View Tweet)
Three Abstracts That May Shape the Future of RA Treatment
Our therapeutic armamentarium in RA keeps on growing. New studies and new molecules, new mechanisms of action or new ways of using old drugs are presented every year at conferences. But which are the ones who can have an https://t.co/CaMSHlkbFD
Dr. John Cush @RheumNow ( View Tweet)
Video
From the Blog
Podcasts
EULAR 2026 RA Topic Panel
CAR-T Topic Panel EULAR 2026
EULAR 2026 PsA Update What's Changing in P
RA Topic Podcast compilation
Therapeutic Updates
Psoriatic arthritis and overweight or obesity
Sponsored by Lilly Medical Affairs
Dr. Merola presenting the results from TOGETHER‑PsA, a phase 3b trial evaluating the concomitant use of an IL‑17A antagonist and an incretin receptor agonist in adults with psoriatic arthritis and overweight or obesity.
Read Post
Poster Hall
Sponsored by AbbVie Medical Affairs + Health Impact
